DoD Melanoma Research Program anticipated funding opportunities for FY22

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.

June 28, 2024

Vol.50 No.26

In Brief

Jeffrey Farma named Fox Chase chair of surgery

Jeffrey M. Farma was appointed chair of surgery at Fox Chase Cancer Center.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting.

May 31, 2024

Vol.50 No.22

Funding Opportunities

DOD Melanoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Melanoma Research Program to support innovative, high-impact melanoma research.

May 17, 2024

Vol.50 No.20

Clinical Roundup

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

February 23, 2024

Vol.50 No.08

Clinical Roundup

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).

October 27, 2023

Vol.49 No.40

DoD Melanoma Research Program anticipated funding opportunities for FY22

YOU MAY BE INTERESTED IN

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Jeffrey Farma named Fox Chase chair of surgery

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

DOD Melanoma Research Program funding opportunities for FY24

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

Renew today!

Subscriber content

Login